Immutep Limited ADR (IMMP) — Research Snapshot

As of 2026-11-08. All figures and statements are drawn from cited sources and should be independently verified before any decision. This is not investment advice.

Company Context

Immutep Limited (ASX: IMM; Nasdaq: IMMP) is a clinical-stage biotechnology company headquartered in Sydney, Australia, developing LAG-3 (lymphocyte activation gene-3) immunotherapies for cancer and autoimmune diseases [3]. It was formerly Prima BioMed and changed its name in November 2017 [27]. CEO is Marc Voigt; CSO is Dr. Frédéric Triebel, who discovered LAG-3 [25].

Data-quality caveat: The provided market-cap figure (~$24.61M as of 2026-11-08) conflicts with the CatalystAlert dossier's ~$39M as of 2026-07-22 [1]. Given Immutep's small float and thin liquidity, such discrepancies are plausible and worth watching.

Recent Catalysts (last ~1–3 months)